Table 5 Frequencies of detailed management actions undertaken by the physicians following positive or negative screening tests.
Problem | All actions | Detailed actions ¶ |  |  | |
|---|---|---|---|---|---|
|  | No | % †|  | No | % †|
Osteoporosis risk assessment (n = 115) | 83 | 72.1 | DXA bone measurement | 76 | 66.1 |
| Â | Â | Â | New prescription of Vitamin D3 and Calcium | 58 | 50.4 |
| Â | Â | Â | New estrogen replacement therapy | 1 | 0.9 |
| Â | Â | Â | Bisphosophonate | 22 | 19.1 |
| Â | Â | Â | Calcitonin | 0 | 0 |
| Â | Â | Â | Selective estrogen-receptor modulator therapy | 1 | 0.9 |
Urinary incontinence (n = 112) | 54 | 47.0 | Pelvic floor muscle training | 21 | 18.8 |
| Â | Â | Â | Change of drug prescription | 7 | 6.3 |
| Â | Â | Â | Planning of in depth exploration by GP | 17 | 15.2 |
| Â | Â | Â | New drug prescription | 15 | 13.4 |
| Â | Â | Â | Referral to urologist or gynaecologist | 11 | 9.8 |
Hearing loss (n = 114) | 39 | 33.9 | Removal of ear wax | 15 | 13.2 |
| Â | Â | Â | Referral to otolaryngologist | 29 | 25.4 |
Fall risk or balance and gait difficulties (n = 115) | 38 | 33.1 | Change of drug prescription | 4 | 3.5 |
| Â | Â | Â | Hip protector | 3 | 2.6 |
| Â | Â | Â | Environmental source exploration | 20 | 17.4 |
| Â | Â | Â | Information on safer footwear | 25 | 21.7 |
| Â | Â | Â | Instructed exercise training | 7 | 6.1 |
| Â | Â | Â | Planning of in-depth exploration by GP | 5 | 4.3 |
Sleep disorder (n = 114) | 33 | 28.7 | New drug prescription | 16 | 14.0 |
| Â | Â | Â | Change of drug prescription | 2 | 1.8 |
| Â | Â | Â | Non- drug therapy | 13 | 11.4 |
| Â | Â | Â | Planning of in-depth exploration by GP | 5 | 4.4 |
Low vision (n = 110) | 29 | 26.4 | Referral to ophthalmologist | 29 | 26.4 |
Pneumococcal vaccination longer than 3 years ago (n = 113) | 23 | 20.0 | Pneumococcal vaccination | 23 | 20.4 |
Depression (n = 114) | 21 | 18.3 | New antidepressant drug therapy | 7 | 6.1 |
| Â | Â | Â | Change of drug prescription | 2 | 1.8 |
| Â | Â | Â | Non-drug treatment | 10 | 8.8 |
| Â | Â | Â | Planning of in-depth exploration by GP | 9 | 7.9 |
| Â | Â | Â | Referral to psychiatrist | 1 | 0.9 |
Influenza vaccination longer than one year ago (n = 114) | 20 | 17.4 | Influenza vaccination | 20 | 17.4 |
Psychosocial deprivation (n = 113) | 14 | 12.3 | Contact with relatives | 7 | 6.1 |
| Â | Â | Â | Contact with neighbours | 4 | 3.5 |
| Â | Â | Â | Contact with community nurse | 6 | 5.3 |
| Â | Â | Â | Contact with social worker | 1 | 0.9 |
Cognitive impairment (n = 114) | 13 | 11.4 | Follow up in six months | 37 | 32.5 |
| Â | Â | Â | Referral to neurologist/psychiatrist | 13 | 11.4 |
Hyperlipidemia at assessment (n = 113) | 9 | 7.9 | Antilipidemic drug treatment | 9 | 7.9 |
Hypertension at assessment (n = 111) | 4 | 3.6 | New or additional drug prescription | 4 | 3.6 |
Hyperglycemia at assessment (n = 112) | 2 | 1.8 | New or additional drug prescription | 2 | 1.8 |